Northwest Biotherapeutics, Inc. (NWBO) - Financial and Strategic SWOT
Analysis Review
Reference Code: GDPH62423FSA Publication Date: JUL 2012
4800 Montgomery Lane, Suite 800 Phone +1 240 4979024 Revenue 0.0 (million USD)
Bethesda, MD Fax Net Profit -32.83 (million USD)
20814 Website www.nwbio.com Employees 8
NWBO [Over The Pharmaceuticals &
United States Exchange Industry
Counter] Healthcare
Company Overview
Northwest Biotherapeutics, Inc. (NW Bio) is a development stage biotechnology company specializing in the discovery,
development and commercialization of immunotherapy products that generate and enhance immune system responses to treat
cancer. The company based on its two basic technology platforms, dendritic cell-based cancer vaccines, called DCVax; and
monoclonal antibodies for cancer therapeutics, has developed a robust pipeline of therapeutic product candidates. The company
focuses in the therapeutic areas of oncology and immunology. The drug pipeline is been developed to treat the cancers related to
brain, lung, liver, head and neck, pancreas, prostrate and ovarian.
Key Executives SWOT Analysis
Name Title Northwest Biotherapeutics, Inc., SWOT Analysis
Linda F. Powers Chief Executive Officer Strengths Weaknesses
Alton L. Boynton, Ph.D. Chief Scientific Officer
Proprietary DCVax Technology Lack of Marketed Products
Robert A. Farmer Director Platform
Weak Financial Performance
Dr. Navid Malik Director
Strong Research and
Jerry Jasinowski Director Development Activities
Source: Annual Report, Company Website, Primary and Secondary
Research, GlobalData
Opportunities Threats
Share Data
Northwest Biotherapeutics, Inc. Product Pipeline Intense Competition
Share Price (USD) as on 09-Jul- 0.23 Market Potential: Cancer Stringent Government
2012 Regulations
EPS (USD) -0.35
Market Cap (million USD) 37 Source: Annual Report, Company Website, Primary and Secondary Research,
GlobalData
Enterprise Value (million USD) 54
Shares Outstanding (million) 163
Source: Annual Report, Company Website, Primary and Secondary
Research, GlobalData
Financial Performance Recent Developments
May 18, 2012 Northwest Biotherapeutics Reports Q1 2012
Results
Apr 13, 2012 Northwest Biotherapeutics Reports 2011
Results
Nov 14, 2011 Northwest Biotherapeutics Reports Q3 2011
Results
Aug 10, 2011 Northwest Biotherapeutics Reports Q2 2011
Results
Source: Annual Report, Company Website, Primary and Secondary Research,
GlobalData
Source: Annual Report, Company Website, Primary and Secondary
Research, GlobalData
Northwest Biotherapeutics, Inc. (NWBO) - Financial and Strategic Reference Code: GDPH62423FSA
SWOT Analysis Review
Source : www.globalcompanyintelligence.com Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
Table of Contents
Table of Contents ............................................................................................................................................................................... 2
List of Tables .................................................................................................................................................................................. 4
List of Figures ................................................................................................................................................................................. 4
Section 1 - About the Company.......................................................................................................................................................... 5
Northwest Biotherapeutics, Inc. - Key Facts ....................................................................................................................................... 5
Northwest Biotherapeutics, Inc. - Key Employees .............................................................................................................................. 6
Northwest Biotherapeutics, Inc. - Key Employee Biographies ............................................................................................................ 7
Northwest Biotherapeutics, Inc. - Major Products and Services ......................................................................................................... 8
Northwest Biotherapeutics, Inc. - Pharmaceutical Pipeline Products Data ......................................................................................... 9
Northwest Biotherapeutics, Inc., Pipeline Products by Therapy Area ............................................................................................. 9
Northwest Biotherapeutics, Inc., Pipeline Products by Development Phase................................................................................. 10
Northwest Biotherapeutics, Inc. - History.......................................................................................................................................... 12
Northwest Biotherapeutics, Inc. - Company Statement .................................................................................................................... 13
Northwest Biotherapeutics, Inc. - Locations And Subsidiaries.......................................................................................................... 14
Head Office ................................................................................................................................................................................... 14
Other Locations & Subsidiaries ..................................................................................................................................................... 14
Section 2 – Company Analysis ......................................................................................................................................................... 15
Northwest Biotherapeutics, Inc. - Business Description ................................................................................................................... 15
Northwest Biotherapeutics, Inc. - SWOT Analysis............................................................................................................................ 16
SWOT Analysis - Overview........................................................................................................................................................... 16
Northwest Biotherapeutics, Inc. - Strengths .................................................................................................................................. 16
Strength - Proprietary DCVax Technology Platform .................................................................................................................. 16
Strength - Strong Research and Development Activities........................................................................................................... 16
Strength - Proprietary Manufacturing System ........................................................................................................................... 16
Strength - Orphan Drug Designation - DCVax-L ....................................................................................................................... 16
Northwest Biotherapeutics, Inc. - Weaknesses............................................................................................................................. 17
Weakness - Lack of Marketed Products .................................................................................................................................... 17
Weakness - Weak Financial Performance ................................................................................................................................ 17
Northwest Biotherapeutics, Inc. - Opportunities ............................................................................................................................ 17
Opportunity - Product Pipeline .................................................................................................................................................. 17
Opportunity - Market Potential: Cancer ..................................................................................................................................... 17
Opportunity - Changing Demographics ..................................................................................................................................... 18
Opportunity - Rising Healthcare Expenditure in the US............................................................................................................. 18
Northwest Biotherapeutics, Inc. - Threats ..................................................................................................................................... 18
Threat - Intense Competition ..................................................................................................................................................... 18
Threat - Stringent Government Regulations .............................................................................................................................. 18
Threat - Cost Containment Pressures ....................................................................................................................................... 18
Threat - Uncertain R&D Outcomes ........................................................................................................................................... 19
Northwest Biotherapeutics, Inc. - Key Competitors .......................................................................................................................... 20
Section 3 – Company Financial Ratios ............................................................................................................................................. 21
Financial Ratios - Capital Market Ratios........................................................................................................................................... 21
Financial Ratios - Annual Ratios ...................................................................................................................................................... 21
Performance Chart ........................................................................................................................................................................... 23
Financial Performance...................................................................................................................................................................... 23
Financial Ratios - Interim Ratios....................................................................................................................................................... 24
Northwest Biotherapeutics, Inc. (NWBO) - Financial and Strategic Reference Code: GDPH62423FSA
SWOT Analysis Review
Source : www.globalcompanyintelligence.com Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
Fina